These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 3443483

  • 1. Urinary inhibitory activity of calcium oxalate monohydrate crystal growth in stone-formers & non stone-formers.
    Sidhu H, Vaidyanathan S, Wangoo D, Rattan V, Thind SK, Nath R, Malakondaiah GC, Tandon SP.
    Indian J Med Res; 1987 Oct; 86():500-5. PubMed ID: 3443483
    [No Abstract] [Full Text] [Related]

  • 2. Glycoprotein calcium oxalate crystal growth inhibitor in urine.
    Worcester EM, Nakagawa Y, Coe FL.
    Miner Electrolyte Metab; 1987 Oct; 13(4):267-72. PubMed ID: 3306319
    [Abstract] [Full Text] [Related]

  • 3. Changes in urinary composition of calcium oxalate stone formers.
    Rahman B, Rahman MA.
    Biomed Pharmacother; 1986 Oct; 40(3):108-10. PubMed ID: 3742009
    [Abstract] [Full Text] [Related]

  • 4. Alpha-1-microglobulin: inhibitory effect on calcium oxalate crystallization in vitro and decreased urinary concentration in calcium oxalate stone formers.
    Tardivel S, Médétognon J, Randoux C, Kébédé M, Drüeke T, Daudon M, Hennequin C, Lacour B.
    Urol Res; 1999 Aug; 27(4):243-9. PubMed ID: 10460893
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Inhibitory effect of bikunin on calcium oxalate crystallization in vitro and urinary bikunin decrease in renal stone formers.
    Médétognon-Benissan J, Tardivel S, Hennequin C, Daudon M, Drüeke T, Lacour B.
    Urol Res; 1999 Aug; 27(1):69-75. PubMed ID: 10092156
    [Abstract] [Full Text] [Related]

  • 8. The most important metabolic risk factors in recurrent urinary stone formers.
    Parvin M, Shakhssalim N, Basiri A, Miladipour AH, Golestan B, Mohammadi Torbati P, Azadvari M, Eftekhari S.
    Urol J; 2011 Aug; 8(2):99-106. PubMed ID: 21656467
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of dietary control of urinary uric acid excretion in calcium oxalate stone formers and non-stone-forming controls.
    Pais VM, Holmes RP, Assimos DG.
    J Endourol; 2007 Feb; 21(2):232-5. PubMed ID: 17338626
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Urinary calcium oxalate crystal growth inhibitors.
    Worcester EM.
    J Am Soc Nephrol; 1994 Nov; 5(5 Suppl 1):S46-53. PubMed ID: 7873744
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Urinary macromolecular substances as natural inhibitors of calcium oxalate crystal aggregation.
    Koide T, Takemoto M, Itatani H, Takaha M, Sonoda T.
    Invest Urol; 1981 Mar; 18(5):382-6. PubMed ID: 6162821
    [Abstract] [Full Text] [Related]

  • 17. Diurnal variations of calcium, phosphorus, and magnesium in normal and calcium oxalate stone-forming urine.
    Ogawa Y, Kitagawa R, Umeyama T.
    Nihon Jinzo Gakkai Shi; 1983 Sep; 25(9):1131-4. PubMed ID: 6686621
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinical characteristics and pathogenetic mechanisms in hyperuricosuric calcium oxalate renal stone disease.
    Favus MJ, Coe FL.
    Scand J Urol Nephrol Suppl; 1980 Sep; 53():171-7. PubMed ID: 6937993
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.